费城染色体阳性,BCR-ABL1 阳性慢性粒细胞白血病的临床试验
总计1041个结果
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)完全的
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)完全的
-
M.D. Anderson Cancer Center撤销
-
Centre Hospitalier Universitaire de Besancon完全的
-
Merck Sharp & Dohme LLC终止白血病,淋巴细胞性,急性 | 骨髓性白血病,急性 | 白血病,淋巴细胞,急性,费城阳性 | Myelogenous Leukemia, Chronic, Aggressive Phase
-
Andrew RezvaniNational Institutes of Health (NIH); Pharmacyclics LLC.完全的
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)完全的
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)终止
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Immunex Corporation撤销急性髓性白血病 | 慢性粒细胞白血病
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)完全的
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)完全的
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)完全的
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)完全的
-
Shenzhen Second People's Hospital招聘中
-
Bristol-Myers Squibb完全的
-
University of LiverpoolImperial College London; Newcastle University; University of Glasgow未知
-
M.D. Anderson Cancer CenterWyeth is now a wholly owned subsidiary of Pfizer完全的
-
Novartis Pharmaceuticals完全的
-
Novartis Pharmaceuticals完全的
-
Gruppo Italiano Malattie EMatologiche dell'Adulto完全的
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb完全的
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)未知
-
Gruppo Italiano Malattie EMatologiche dell'Adulto完全的
-
Australasian Leukaemia and Lymphoma GroupMerck Sharp & Dohme LLC; Novartis Pharmaceuticals未知
-
M.D. Anderson Cancer CenterJohnson & Johnson Pharmaceutical Research & Development, L.L.C.完全的
-
Seoul St. Mary's HospitalBristol-Myers Squibb未知